Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8042099 | 0.84 | SIGMAR1 (0.53) | SIGMAR1SMN1; SMN2MEN1KMT2ACHRM5 | |
| SCHEMBL9081026 | 0.82 | PSMB1 (0.42) | SIGMAR1SMN1; SMN2MEN1KMT2ALTA4H | |
| SCHEMBL21348721 | 0.81 | SIGMAR1 (0.50) | SIGMAR1SMN1; SMN2MEN1KMT2ACHRM5 | |
| SCHEMBL11617060 | 0.81 | SIGMAR1 (0.50) | SIGMAR1SMN1; SMN2MEN1KMT2ACHRM5 | |
| SCHEMBL28882656 | 0.80 | PSMB1 (0.45) | MEN1KMT2ALTA4H | |
| SCHEMBL8805120 | 0.80 | PSMB1 (0.45) | MEN1KMT2ALTA4H | |
| Hydrochloric Acid SCHEMBL28362752 | 0.79 | SIGMAR1 (0.45) | SIGMAR1SMN1; SMN2MEN1KMT2ACHRM5 | |
| SCHEMBL28705809 | 0.78 | CXCR4 (0.52) | SIGMAR1SMN1; SMN2MEN1KMT2ACHRM5 | |
| SCHEMBL14141934 | 0.78 | SIGMAR1 (0.47) | SIGMAR1SMN1; SMN2MEN1KMT2ACHRM5 | |
| SCHEMBL19983456 | 0.77 | SIGMAR1 (0.50) | SIGMAR1SMN1; SMN2MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420807-B2 | Process for the preparation of quetiapine | FERMION OY (FI) | 2013-04-16 | — | — | US | claimed |
| US-8389716-B2 | Process for the synthesis of quetiapine | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2013-03-05 | — | — | US | claimed |
| EP-2245021-B1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE | FERMION OY (FI) | 2012-09-12 | — | — | EP | claimed |
| US-20110118460-A1 | PROCESS FOR THE SYNTHESIS OF QUETIAPINE | F.I.S. FABBRICA ITALIANA SINTETICI S.P.A (IT) | 2011-05-19 | — | — | US | claimed |
| US-20110112290-A1 | PROCESS FOR THE PREPARATION OF QUETIAPINE | FERMION OY (FI) | 2011-05-12 | — | — | US | claimed |
| EP-1664009-B1 | PREPARATION METHOD FOR QUETIAPINE | FERMION OY (FI) | 2011-01-19 | — | — | EP | claimed |
| US-7858777-B2 | Preparation method for quetiapine | FERMION OY (FI) | 2010-12-28 | — | — | US | claimed |
| EP-2245021-A1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE | Fermion Oy (FI) | 2010-11-03 | — | — | EP | claimed |
| WO-2009095529-A1 | A PROCESS FOR THE PREPARATION OF QUETIAPINE | FERMION OY (FI) | 2009-08-06 | — | — | WO | claimed |
| US-20070111986-A1 | Preparation method for quetiapine | FERMION OY (FI) | 2007-05-17 | — | — | US | claimed |
| JP-2007505865-A | — | — | 2007-03-15 | — | — | JP | claimed |
| EP-1664009-A1 | PREPARATION METHOD FOR QUETIAPINE | Fermion Oy (FI) | 2006-06-07 | — | — | EP | claimed |
| WO-2006027789-A1 | PROCESS FOR PRODUCING 11-[4-[2-(2-HYDROXYETHOXY)ETHYL]-1-PIPERAZINYL]DIBENZO[b,f][1,4]THIAZEPINE AND A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | JUBILANT ORGANOSYS LIMITED (IN) | 2006-03-16 | — | — | WO | claimed |
| WO-2005028459-A1 | PREPARATION METHOD FOR QUETIAPINE | FERMION OY (FI) | 2005-03-31 | — | — | WO | claimed |
| US-5736623-A | OXIDATIVE POLYMERIZATION; NEUTRALIZATION | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 1998-04-07 | — | — | US | claimed |
| EP-0240228-B1 | THIAZEPINE COMPOUNDS | ICI AMERICAS INC. (US) | 1990-11-07 | — | — | EP | claimed |
| US-12584083-B2 | Surface treatment composition, surface treatment method, and method for producing semiconductor substrate | FUJIMI INCORPORATED (JP) | 2026-03-24 | — | — | US | disclosed |
| EP-4606929-A1 | ETCHING SOLUTION, REPLENISHMENT SOLUTION, AND METHOD FOR FORMING COPPER WIRING | MEC Company Ltd. (JP) | 2025-08-27 | — | — | EP | disclosed |
| EP-0230402-A2 | Pharmacologically active alkylol derivatives | DOMPE' FARMACEUTICI S.p.A. (IT) | 1987-07-29 | — | — | EP | disclosed |
| US-4097597-A | ANTISCHIZOPHRENICS | ABBOTT LABORATORIES (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112290-A1 | PROCESS FOR THE PREPARATION OF QUETIAPINE | CYP3A5, QDPR, HTR5A | SIGMAR1 212/4885SMN1; SMN2 4517/4885MEN1 4283/4885 |
| US-12584083-B2 | Surface treatment composition, surface treatment method, and method for producing semiconductor substrate | PIEZO1, TYRO3, ACP1 | SIGMAR1 133/4885SMN1; SMN2 1007/4885MEN1 3230/4885 |
| US-20070111986-A1 | Preparation method for quetiapine | CYP3A5, COMT, CYP51A1 | SIGMAR1 1878/4885SMN1; SMN2 4431/4885MEN1 3429/4885 |
| US-20110118460-A1 | PROCESS FOR THE SYNTHESIS OF QUETIAPINE | CYP4F11, MAOB, CYP2F1 | SIGMAR1 412/4885SMN1; SMN2 4797/4885MEN1 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.